Series Overview:
The Perelman School of Medicine at the University of Pennsylvania and ViralEd are proud to announce the extension of this ground-breaking CME activity. Mirroring academic grand rounds programs, these CME-certified sessions combine traditional academic grand rounds with the innovation and convenience of telemedicine. The "HIV Grand Rounds from the Perelman School of Medicine at the University of Pennsylvania" is delivered live via the Internet every Thursday at 12:00pm Eastern Time and is available for on-demand viewing immediately following the live broadcast.
Presentations cover the most important and current topics in HIV/AIDS and are delivered by the top experts in the field. They are designed to be immediately relevant to practicing HIV clinicians and many are case-based. The final 10 minutes of each one-hour educational activity consists of a live question and answer period, with the presenting faculty member available to answer questions asked by attendees using the webinar interface. These weekly grand rounds are intended to provide clinicians with convenient and easily accessible knowledge and clinical skills they need to provide the best medical care for their HIV-positive patients.
Each session may be broadcast via your Internet connection in your conference room or auditorium for large groups to view, or individually to your personal computer at your convenience. Simply register at www.viraled.com/grandrounds for easy access.
Target Audience:
The program has been designed for physicians, fellows, residents, medical students, nurses, nurse practitioners, physician assistants and allied health professionals in the medical specialties of Dermatology, Nephrology, Hematology/Oncology and Psychiatry as well as OB/GYN physicians, Osteo-specialists, Infectious Disease specialists, Public Health professionals and other clinicians interested and involved in the care of patients with HIV/AIDS.
Commercial Support Acknowledgement:
HIV Grand Rounds is supported by educational grants from Merck and Co., Inc., Gilead Sciences and Bristol-Myers Squibb.
Learning Objectives for the Series:
Upon completion of the educational activity, participants should be able to:
-
Improve knowledge and ability to use ARV therapy successfully;
-
Improve the knowledge of how drug adverse events, drug pharmacokinetics and patient adherence can affect ARV success and through the application of this knowledge avoid morbidity and mortality;
-
Improve knowledge of opportunistic infections and co-morbidities that may affect HIV-positive patients and increase their risk for morbidity and Mortality;
-
Improve understanding of the importance of individualizing the care of each HIV-positive patient.
PROGRAM FACULTY:
 |
Mark Sulkowski, MD
Professor of Medicine
Johns Hopkins University School of Medicine
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology/Hepatology
Johns Hopkins Department of Medicine
Baltimore, Maryland
|
|
|
| |
|
|
|
Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Perelman School of Medicine at the University of Pennsylvania and ViralEd, Inc. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement:
The Perelman School of Medicine at the University of Pennsylvania designates each live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures:
It is policy at the Perelman School of Medicine at the University of Pennsylvania and ViralEd, Inc. for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity. For this purpose we consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania (Rodman Campbell, Mila Kostic, Michael Schoen, PhD and Mindy Pollock Troy), our educational partner ViralEd, Inc. (Richard Gordon, Brian Boyle, MD, JD), and the peer reviewer, Zalman Agus, MD, Associate Dean for Continuing Medical Education, have reported that they have no relevant financial relationships with any commercial interests related to the content of this educational activity.
The following faculty or planning committee members have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity:
The following faculty or planning committee members have reported the listed relevant financial relationships with commercial interests related to the content of this educational activity:
Faculty/Planning Committee Disclosures:
|
Mark Sulkowski, MD
|
Abbvie, Gilead, Janssen, Merck
|
Research Support (to JHU)
|
| |
ABBVIE, COCRYSTAL, GILEAD,JANSSEN, MERCK, TREK
|
Advisor/Consultant
|
|
Ian Frank, MD
|
Gilead
|
Advisory Board
|
| |
VIIV/GlaxoSmith Kline, Bavarian Nordic
|
Research Support
|
Discussion of Investigational and/or Off-label Use of commercial products and devices:
The Perelman School of Medicine at the University of Pennsylvania requires all faculty to disclose any discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
Faculty members will disclose to participants any discussions of off-label and/or investigational uses of pharmaceutical products within their presentations.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
register:
